Bayer AG has identified fused pyrimidines GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Shenzhen Forward Pharmaceuticals Co. Ltd. has synthesized quinazoline derivatives acting as GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer, particularly lung cancer.

Tyligand Bioscience Ltd. has disclosed GTPase KRAS (G12C mutant) inhibitors reported to be useful for the treatment of cancer.

Medshine Discovery Inc. has divulged GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Shanghai Apeiron Biotechnology Co. Ltd. has divulged GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Researchers at 3D Medicines (Beijing) Co. Ltd. and 3D Medicines Inc. have divulged GTPase KRAS (mutant) inhibitors reported to be useful for the treatment of cancer.

Guangzhou Lupeng Pharmaceutical Co. Ltd. and Newave Pharmaceutical LLC have divulged (mutant) ligands reported to be useful for the treatment of cancer, autoimmune disease and inflammation.

3D Medicines (Beijing) Co. Ltd. has disclosed pyridopyrimidine derivative GTPase KRAS...

Abbisko Therapeutics Co. Ltd. has disclosed GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Research at Incyte Corp. has led to the development of hetero-tricyclic compounds acting as GTPase KRAS (mutant) inhibitors and thus reported to be useful for the treatment of cancer, inflammatory and immunological disorders.